Cristal Delivery’s portfolio covers indications as infectious diseases, immunology and oncology and at present contains the following products at different stages of development:
Various experimental studies have provided clear proof of CriPec® and resulting products. Data packages can be obtained upon request and the products listed above are available for licensing.
This proprietary product portfolio is currently being expanded. Our strategy focuses thereby at CriPec® based drugs products that can bring significant benefits to the patient, clinician and company. Product opportunities include the development of drug molecules that previously failed, improvement of the performance of known products (line extension and life-cycle management) and the application in other therapeutic areas.